Partner with {keyword} or similar agencies in Europe and LATAM

During the due diligence time, Kamil, our CTO, took upon himself the task of reverse-engineering and documenting the API. It took him over two weeks of careful study to get to know the code well, and the work accelerated from there.


Starting from the very foundation

This was no ordinary project for us. It was an exhilarating challenge that demanded the translation of theoretical knowledge into a concrete web application. To achieve this transformation, we swiftly assembled a full web app team, with Kamil, our co-founder, leading the tech frontier, and Adrian, our CEO, overseeing the project management.


Transforming academic vision

We were amid this transformative process, Chematica transitioned ownership from Grzybowski Scientific Inventions Ltd. to MilliporeSigma (Merck). During the due diligence that preceded the purchase, Kamil Śliwak became an unofficial CTO. He was indispensable, offering deep technical insights that proved crucial during the acquisition talks. In fact, Kamil was the go-to person for Merck's technical queries, underlining our active participation in the sales process. While we didn't contribute to the scientific backbone of Chematica, we certainly feel like co-authors of the project. This experience embodies our brand archetype, the Creator, exemplifying our capability to bring an idea to commercial success. This wasn't just a testament to our team's hard work but also a validation of our commitment to excellence. The acquisition marked a significant milestone, symbolizing Chematica's elevation from an academic initiative to a commercial powerhouse.


Global Pharma Acquisition

Learn how Code Poets worked with Chematica and how they can support your BioTech product and team.

Code Poets Success Story in BioTech for Chematica - A case study | 2024

Moving away from merely replicating the desktop app’s functionalities, we collaborated closely with the client, striving to craft features that met users' contemporary needs.


User Experience (UX) required a significant upgrade

We then identified the project's core issue: its instability, mainly because it was developed by chemists rather than programmers. Though functional, Chematica wasn’t ready for mass commercial usage. This necessitated us to streamline its backend, which was originally a potpourri of Java, C++, Python, and CoffeeScript.


Code's instability

Shifting from a chemical desktop app to a modern web application was no easy task. One of our initial hurdles was the computational chemical backend – a vital element of Chematica that had little to no API documentation.

During the due diligence time, Kamil, our CTO, took upon himself the task of reverse-engineering and documenting the API. It took him over two weeks of careful study to get to know the code well, and the work accelerated from there.


Lack of documentation

Security was paramount. Given the significance of IP protection in the pharmaceutical sphere, we invested heavily in ensuring the code was production-ready, secure, and scalable.

Some of our key security measures included:

Whitelist identifying,

Multi-factor authorization,

Enforcing continuous security baseline compliance,

Asymmetric encryption algorithms,

Hashing algorithms.

In the following months after the acquisition, rigorous pen tests and thorough security scans were conducted by an external entity, where Chematica stood tall with no major issues.


Security & IP protection

The client stakeholders at Chematica were working closely with the team at Code Poets

From Academic Vision to Global Pharma Acquisition

Code Poets

"We entered the project at a critical stage in its lifecycle, when the time finally came to turn it from a rough research prototype into a production-ready application that could withstand contact with actual users. It was severely lacking in scalability, UX and good development practices. What really mattered, though, was that it had solid scientific foundations and we could work with domain experts. We could handle the rest."
